rofecoxib has been researched along with Hypertension in 47 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 9.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 9.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "In patients with osteoarthritis treated for 12 weeks, rofecoxib, 25 mg/d, was as effective as naproxen, 500 mg twice daily, but had statistically significantly superior GI tolerability and led to less use of concomitant GI medications." | 9.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| "The aim of the study was to investigate the effects of the cylooxygenase (COX)-2 specific inhibitor rofecoxib, on blood pressure (BP) and heart rate (HR) in patients with well-controlled hypertension and osteoarthritis via 24-h ambulatory monitoring." | 7.73 | The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis. ( Altok, KR; Arinsoy, T; Aydin, M; Ayerden-Ebinc, F; Derici, U; Erten, Y; Goker, B; Haznedaroglu, S; Sindel, S, 2005) |
| "Domestic (US) cases of apparently unconfounded, acute hypertension leading to hospitalisation were collected and reviewed from the spontaneous adverse events database of the FDA for rofecoxib, celecoxib, nabumetone and oxaprozin for the initial 3 years of marketing." | 7.72 | Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. ( Beitz, J; Bonnel, R; Brinker, A; Goldkind, L, 2004) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 7.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "Celecoxib was a less costly treatment option than rofecoxib among OA patients with hypertension aged > or = 65 years, based on our model of the direct costs of COX-2 specific inhibitor therapy combined with those associated with physician monitoring and treatment of edema and BP destabilization." | 7.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 7.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "Rofecoxib also reduced cardiac hypertrophy." | 5.33 | Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. ( de Champlain, J; Laplante, MA; Wu, R, 2005) |
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 5.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| " Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis." | 5.11 | The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. ( Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N, 2005) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 5.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "In patients with osteoarthritis treated for 12 weeks, rofecoxib, 25 mg/d, was as effective as naproxen, 500 mg twice daily, but had statistically significantly superior GI tolerability and led to less use of concomitant GI medications." | 5.10 | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ( Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS, 2003) |
| " Key search terms included COX-2 selective inhibitors; anti-inflammatory agents, nonsteroidal; celecoxib; rofecoxib; and hypertension." | 4.82 | Effect of cyclooxygenase-2 inhibitors on blood pressure. ( Hisel, TM; Johnson, DL; Phillips, BB, 2003) |
| " Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index." | 3.74 | Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008) |
| "In view of the ongoing controversy of cardiorenal safety of selective COX-2 inhibitors (coxibs), the present study was designed to examine the effects of 2 different coxibs, celecoxib and rofecoxib, compared with a traditional NSAID, diclofenac, and placebo on renal morphology and function in salt-sensitive hypertension." | 3.73 | Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. ( Bühler, N; Camici, G; Chenevard, R; Gröne, HJ; Hermann, M; Kiss, E; Lüscher, TF; Ruschitzka, F; Shaw, S, 2005) |
| "Switching patients from celecoxib to rofecoxib resulted in an increase in BP, with a larger difference observed in patients with hypertension." | 3.73 | Blood pressure in Native Americans switched from celecoxib to rofecoxib. ( Diggins, DA; Fredy, J; Morrill, GB, 2005) |
| "The aim of the study was to investigate the effects of the cylooxygenase (COX)-2 specific inhibitor rofecoxib, on blood pressure (BP) and heart rate (HR) in patients with well-controlled hypertension and osteoarthritis via 24-h ambulatory monitoring." | 3.73 | The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis. ( Altok, KR; Arinsoy, T; Aydin, M; Ayerden-Ebinc, F; Derici, U; Erten, Y; Goker, B; Haznedaroglu, S; Sindel, S, 2005) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 3.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "Domestic (US) cases of apparently unconfounded, acute hypertension leading to hospitalisation were collected and reviewed from the spontaneous adverse events database of the FDA for rofecoxib, celecoxib, nabumetone and oxaprozin for the initial 3 years of marketing." | 3.72 | Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. ( Beitz, J; Bonnel, R; Brinker, A; Goldkind, L, 2004) |
| "These data show that celecoxib but not rofecoxib or diclofenac improves endothelial dysfunction and reduces oxidative stress, thus pointing to differential effects of coxibs in salt-induced hypertension." | 3.72 | Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. ( Camici, G; Fiedler, M; Fratton, A; Gay, RE; Gay, S; Hellermann, JP; Hermann, M; Hurlimann, D; Lüscher, TF; Neidhart, M; Ruschitzka, F; Tanner, FC; Thiery, J, 2003) |
| "Celecoxib was a less costly treatment option than rofecoxib among OA patients with hypertension aged > or = 65 years, based on our model of the direct costs of COX-2 specific inhibitor therapy combined with those associated with physician monitoring and treatment of edema and BP destabilization." | 3.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "These findings suggest a higher risk of admission for congestive heart failure in users of rofecoxib and non-selective NSAIDs, but not celecoxib, relative to non-NSAID controls." | 3.72 | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. ( Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Lee, DS; Mamdani, M; Naglie, G; Rochon, PA; Stukel, TA, 2004) |
| " Five days before admission, rofecoxib, a new selective COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID), was added for leg pain." | 3.71 | Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. ( Armoni, M; Bukish, N; Derazon, H; Hay, E; Katz, L; Kruglyakov, I, 2002) |
| "The aim of this study was to describe physician-reported management of clinically significant edema and/or destabilized blood pressure in patients with osteoarthritis (OA) and hypertension when initiating therapy with rofecoxib or celecoxib." | 3.71 | Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. ( Bristol, S; Burke, TA; May, C; Osterhaus, JT; Wentworth, C; Whelton, A, 2002) |
| "To determine the costs of heart failure in hypertensive patients receiving celecoxib, rofecoxib, and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice." | 3.71 | Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. ( Burke, TA; Henderson, SC; von Allmen, H; Whelton, A; Zhao, SZ, 2002) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 3.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "Rofecoxib caused an increase in BP compared to celecoxib; a change in recumbent systolic BP +/- SD (6." | 2.72 | Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? ( Aw, TJ; Billah, B; Krum, H; Liew, D; Morel-Kopp, MC; Schneider, HG; Tofler, GH, 2006) |
| "Rofecoxib (Vioxx) was withdrawn from the market because of increased death from cardiovascular (CV) events." | 2.43 | Cardiovascular issues of COX-2 inhibitors and NSAIDs. ( Chowienczyk, P; Kirkham, B; Wong, M, 2005) |
| "MNA, however, did not affect venous thrombosis." | 1.34 | 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. ( Adamus, J; Bartus, M; Buczko, W; Chlopicki, S; Gebicki, J; Lomnicka, M; Mogielnicki, A; Swies, J, 2007) |
| "Osteoarthritis and hypertension are highly prevalent among older Americans." | 1.33 | Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? ( Coupal, L; Grover, SA; Zowall, H, 2005) |
| "Rofecoxib also reduced cardiac hypertrophy." | 1.33 | Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. ( de Champlain, J; Laplante, MA; Wu, R, 2005) |
| "Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1." | 1.32 | Relationship between COX-2 specific inhibitors and hypertension. ( Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH, 2004) |
| "To determine if changes in blood pressure and changes in class or dosing of antihypertensive drugs were significantly different in patients treated with celecoxib versus rofecoxib, two cyclooxygenase (COX)-2 inhibitors." | 1.32 | Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. ( Dickerson, LM; Nietert, PJ; Ornstein, SM; Rothenberg, RJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.13) | 18.2507 |
| 2000's | 44 (93.62) | 29.6817 |
| 2010's | 2 (4.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blankfield, RP | 1 |
| Iftikhar, IH | 1 |
| Nadareishvili, Z | 1 |
| Michaud, K | 1 |
| Hallenbeck, JM | 1 |
| Wolfe, F | 2 |
| Simon, LS | 2 |
| White, WB | 4 |
| Elliott, WJ | 1 |
| Hay, E | 1 |
| Derazon, H | 1 |
| Bukish, N | 1 |
| Katz, L | 1 |
| Kruglyakov, I | 1 |
| Armoni, M | 1 |
| Osterhaus, JT | 1 |
| Burke, TA | 4 |
| May, C | 1 |
| Wentworth, C | 1 |
| Whelton, A | 5 |
| Bristol, S | 1 |
| Bello, AE | 2 |
| Puma, JA | 1 |
| Fort, JG | 3 |
| Zhao, SZ | 2 |
| von Allmen, H | 2 |
| Henderson, SC | 2 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Johnson, DL | 1 |
| Hisel, TM | 1 |
| Phillips, BB | 1 |
| Weaver, A | 1 |
| Alderman, M | 1 |
| Sperling, R | 1 |
| Becker, RV | 1 |
| McCoy, MA | 1 |
| Trotter, JP | 1 |
| Lisse, JR | 1 |
| Perlman, M | 1 |
| Johansson, G | 1 |
| Shoemaker, JR | 1 |
| Schechtman, J | 1 |
| Skalky, CS | 1 |
| Dixon, ME | 1 |
| Polis, AB | 1 |
| Mollen, AJ | 1 |
| Geba, GP | 1 |
| Hermann, M | 2 |
| Camici, G | 2 |
| Fratton, A | 1 |
| Hurlimann, D | 1 |
| Tanner, FC | 1 |
| Hellermann, JP | 1 |
| Fiedler, M | 1 |
| Thiery, J | 1 |
| Neidhart, M | 1 |
| Gay, RE | 1 |
| Gay, S | 1 |
| Lüscher, TF | 2 |
| Ruschitzka, F | 2 |
| Nietert, PJ | 1 |
| Ornstein, SM | 1 |
| Dickerson, LM | 1 |
| Rothenberg, RJ | 1 |
| Brinker, A | 1 |
| Goldkind, L | 1 |
| Bonnel, R | 1 |
| Beitz, J | 1 |
| Zhao, S | 1 |
| Pettitt, D | 1 |
| Mamdani, M | 1 |
| Juurlink, DN | 1 |
| Lee, DS | 1 |
| Rochon, PA | 1 |
| Kopp, A | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Stukel, TA | 1 |
| Solomon, DH | 1 |
| Schneeweiss, S | 1 |
| Levin, R | 1 |
| Avorn, J | 1 |
| Lamarque, D | 1 |
| Grover, SA | 1 |
| Coupal, L | 1 |
| Zowall, H | 1 |
| Chang, IJ | 1 |
| Harris, RC | 1 |
| Shaw, S | 1 |
| Kiss, E | 1 |
| Bühler, N | 1 |
| Chenevard, R | 1 |
| Gröne, HJ | 1 |
| Goldstein, JL | 1 |
| Spalding, W | 1 |
| Suh, S | 1 |
| Sowers, JR | 1 |
| Pitt, B | 1 |
| Winer, N | 1 |
| Kivitz, A | 1 |
| van Ingen, H | 1 |
| Brabant, T | 1 |
| Torg, J | 1 |
| Fredy, J | 1 |
| Diggins, DA | 1 |
| Morrill, GB | 1 |
| Wu, R | 1 |
| Laplante, MA | 1 |
| de Champlain, J | 1 |
| Derici, U | 1 |
| Goker, B | 1 |
| Ayerden-Ebinc, F | 1 |
| Altok, KR | 1 |
| Erten, Y | 1 |
| Haznedaroglu, S | 1 |
| Aydin, M | 1 |
| Arinsoy, T | 1 |
| Sindel, S | 1 |
| Durrieu, G | 1 |
| Olivier, P | 1 |
| Montastruc, JL | 1 |
| Wong, M | 1 |
| Chowienczyk, P | 1 |
| Kirkham, B | 1 |
| Kotob, F | 1 |
| de Leon-Casasola, OA | 1 |
| Lema, MJ | 1 |
| Fries, S | 1 |
| Grosser, T | 1 |
| Price, TS | 1 |
| Lawson, JA | 1 |
| Kapoor, S | 1 |
| DeMarco, S | 1 |
| Pletcher, MT | 1 |
| Wiltshire, T | 1 |
| FitzGerald, GA | 1 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Aw, TJ | 1 |
| Liew, D | 1 |
| Tofler, GH | 1 |
| Schneider, HG | 1 |
| Morel-Kopp, MC | 1 |
| Billah, B | 1 |
| Krum, H | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Chlopicki, S | 1 |
| Swies, J | 1 |
| Mogielnicki, A | 1 |
| Buczko, W | 1 |
| Bartus, M | 1 |
| Lomnicka, M | 1 |
| Adamus, J | 1 |
| Gebicki, J | 1 |
| Brown, CH | 1 |
| Wardle, EN | 1 |
| Fleming, M | 1 |
| Gertz, BJ | 1 |
| Krupa, D | 1 |
| Bolognese, JA | 1 |
| Sperling, RS | 1 |
| Reicin, A | 1 |
| Reitblat, T | 1 |
| Zamir, D | 1 |
| Estis, L | 1 |
| Priluk, R | 1 |
| Drogenikov, T | 1 |
| Viskoper, JR | 1 |
7 reviews available for rofecoxib and Hypertension
| Article | Year |
|---|---|
COX-2 selective inhibitors and heart health.
Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; | 2005 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Dic | 2010 |
Effect of cyclooxygenase-2 inhibitors on blood pressure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2003 |
Are all COX-2 inhibitors created equal?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Hype | 2005 |
Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Protocols; Cyclooxygenase | 2005 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
6 trials available for rofecoxib and Hypertension
| Article | Year |
|---|---|
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; | 2002 |
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method | 2005 |
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determi | 2005 |
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2006 |
Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
Topics: Aged; Aldosterone; Blood Pressure; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Femal | 2006 |
34 other studies available for rofecoxib and Hypertension
| Article | Year |
|---|---|
Food and drug administration regulation of drugs that raise blood pressure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cyclobutanes; Drug Approval; Humans; Hypert | 2015 |
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2008 |
Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cyclooxygenase Inhibitors; Diet; Drug Interactions; | 2002 |
Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
Topics: Celecoxib; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Diuretics; Edema; Humans; Hypertensio | 2002 |
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional S | 2002 |
Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2002 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
Anti-inflammatory drugs may put on the pressure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase Inhibitors; Human | 2003 |
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox | 2003 |
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Costs and Cost Analysis; C | 2003 |
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2003 |
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cycloo | 2003 |
Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antihypertensive Agents; Blood Pressure; Celecoxib; Chi-Sq | 2003 |
Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox | 2004 |
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; | 2004 |
Hypertension associated with therapies to treat arthritis and pain.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 2004 |
Relationship between COX-2 specific inhibitors and hypertension.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; C | 2005 |
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.
Topics: Animals; Blood Pressure; Blood Vessels; C-Reactive Protein; CD8-Positive T-Lymphocytes; Celecoxib; C | 2005 |
Vioxx and Merck: a preventable situation?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Industry; Humans; Hypertensi | 2005 |
Blood pressure in Native Americans switched from celecoxib to rofecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arizona; Blood Pressure; Ce | 2005 |
Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiomegaly; Cells, Cult | 2005 |
The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Pressure Monitoring, Ambulator | 2005 |
COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2005 |
NSAIDs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular System; Clinical Trials as Topic; D | 2005 |
1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.
Topics: Animals; Aorta; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Epoprostenol; Fibrinolytic Agents; Hy | 2007 |
Rofecoxib for osteoarthritis and pain.
Topics: Analgesics; Cyclooxygenase Inhibitors; Diarrhea; Drug Interactions; Dyspepsia; Edema; Enzyme Inhibit | 1999 |
Effect of rofecoxib on the antihypertensive activity of lisinopril.
Topics: Antihypertensive Agents; Drug Interactions; Enzyme Inhibitors; Humans; Hypertension; Lactones; Lisin | 2000 |
Cyclo-oxygenase-2 inhibitors to treat gastrointestinal bleeding.
Topics: Cyclooxygenase Inhibitors; Gastrointestinal Hemorrhage; Humans; Hypertension; Kidney; Lactones; Sulf | 2001 |
Cardiovascular events and COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials, Phase II as Topic; Clinic | 2002 |
The different patterns of blood pressure elevation by rofecoxib and nabumetone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Butanones; Circadian Rhythm; Female; Humans | 2002 |